CpG motifs in bacterial DNA trigger direct B-cell activation
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Unmethylated CpG dinucleotides are more frequent in the genomes of bacteria and viruses than of vertebrates. We report here that bacterial DNA and synthetic oligodeoxynucleotides containing unmethylated CpG dinucleotides induce murine B cells to proliferate and secrete immunoglobulin in vitro and in vivo. This activation is enhanced by simultaneous signals delivered through the antigen receptor. Optimal B-cell activation requires a DNA motif in which an unmethylated CpG dinucleotide is flanked by two 5' purines and two 3' pyrimidines. Oligodeoxynucleotides containing this CpG motif induce more than 95% of all spleen B cells to enter the cell cycle. These data suggest a possible evolutionary link between immune defence based on the recognition of microbial DNA and the phenomenon of 'CpG suppression' in vertebrates. The potent immune activation by CpG oligonucleotides has implications for the design and interpretation of studies using 'antisense' oligonucleotides and points to possible new applications as adjuvants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Unmethylated CpG motifs in bacterial DNA are potent triggers of inflammation (Klinman et al., 1997; Krieg et al., 1995).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Krieg et al., 1995
In the citing paper
“CpG DNA is a potent stimulator of TLR9 (12).”
From Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice (2011) · cites this paper as [12]
Citations
Cites
Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?
Stein, C. A., & Cheng, Y.-C. (1993) · Science · doi:10.1126/science.8351515 · Cited by 1,303
Gene inhibition using antisense oligodeoxynucleotides
Wagner, R. W. (1994) · Nature · doi:10.1038/372333a0 · Cited by 736
CpG islands as gene markers in the vertebrate nucleus
Bird, A. P. (1987) · Trends in Genetics · doi:10.1016/0168-9525(87)90294-0 · Cited by 678
Current concepts in antisense drug design
Milligan, J. F., Matteucci, M. D., & Martin, J. C. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00066a001 · Cited by 566
Richardson, B., Scheinbart, L., Strahler, J., Gross, L., Hanash, S., & Johnson, M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780331109 · Cited by 562
Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal, S., Temsamani, J., & Tang, J. Y. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7595 · Cited by 561
Therapeutic Applications of Oligonucleotides
Crooke, S. T. (1992) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.32.040192.001553 · Cited by 446
Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
Messina, J. P., Gilkeson, G. S., & Pisetsky, D. S. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.6.1759 · Cited by 371
Lymphocyte stimulation: a rapid multiparameter analysis.
Darzynkiewicz, Z., Traganos, F., Sharpless, T., & Melamed, M. R. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.8.2881 · Cited by 347
Frequency of B lymphocytes responsive to anti-immunoglobulin.
Defranco, A. L., Raveche, E. S., Asofsky, R., & Paul, W. E. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.5.1523 · Cited by 293
Research works printed but not linked: 1
- Krapf, F., Herrmann, M., Leitmann, W. & Kalden, J. R. Clin. exp. immun. 75, 336–342 (1989).
Cited by
Items 601–700 of 1,013
Antisense therapeutics: from theory to clinical practice
Pirollo, K. F., Rait, A. S., Sleer, L. S., & Chang, E. H. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00053-6 · Cited by 124
Equils, O., Schito, M. L., Karahashi, H., Madak‐Erdogan, Z., Yarali, A., Michelsen, K. S., Sher, A., & Arditi, M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5159 · Cited by 113
CpG Oligodeoxyneucleotides as TLR9 Agonists: Therapeutic Applications in Cancer
Murad, Y. M., & Clay, T. M. (2009) · BioDrugs · doi:10.2165/11316930-000000000-00000 · Cited by 110
Anders, H., Banas, B., Linde, Y., Weller, L., Cohen, C. D., Kretzler, M., Martin, S., Vielhauer, V., Schlöndorff, D., & Gröne, H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000042169.23931.73 · Cited by 114
Sandler, A. D., Chihara, H., Kobayashi, G., Zhu, X., Miller, M. A., Scott, D. L., & Krieg, A. Μ. (2003) · PubMed · Cited by 106
Self-citationMartín‐Orozco, E., Kobayashi, H., Uden, J. H. V., Nguyen, M.-D., Kornbluth, R. S., & Raz, E. (1999) · International Immunology · doi:10.1093/intimm/11.7.1111 · Cited by 108
Bacterial DNA activates human neutrophils by a CpG‐independent pathway
Trevani, A. S., Chorny, A., Salamone, G. V., Vermeulen, M. E., Gamberale, R., Schettini, J. L., Raiden, S., & Geffner, J. R. (2003) · European Journal of Immunology · doi:10.1002/eji.200324334 · Cited by 105
Toll-like receptor 7 and 9 defects in common variable immunodeficiency
Yu, J. E., Knight, A. K., Radigan, L., Marron, T. U., Zhang, L., Sánchez‐Ramón, S., & Cunningham‐Rundles, C. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.019 · Cited by 106
Sensible use of antisense: how to use oligonucleotides as research tools
Myers, K. J., & Dean, N. M. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01420-0 · Cited by 105
Immune responses to DNA vaccines
Kowalczyk, D. W., & Ertl, H. C. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050330 · Cited by 106
Inflammatory responses following direct injection of plasmid DNA into skeletal muscle
McMahon, J. M., Wells, K., Bamfo, J., Cartwright, M., & Wells, D. J. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300718 · Cited by 106
Oligonucleotide Adjuvants for T Helper 1 (Th1)–specific Vaccination
Carson, D. A., & Raz, E. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1621 · Cited by 112
Srivastava, S., Jackson, C., Kim, T., Choi, J. H., & Lim, M. K. (2019) · Cancers · doi:10.3390/cancers11040537 · Cited by 113
Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines
Vajdy, M., Srivastava, I. K., Polo, J., Donnelly, J., O’Hagan, D. T., & Singh, M. (2004) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2004.01288.x · Cited by 105
TLR9 and the Recognition of Self and Non‐Self Nucleic Acids
LAMPHIER, M. S., SIROIS, C. M., VERMA, A., GOLENBOCK, D. T., & LATZ, E. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1348.005 · Cited by 106
Deng, J. C., Moore, T. A., Newstead, M. W., Zeng, X., Krieg, A. Μ., & Standiford, T. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5148 · Cited by 104
Self-citationLeptin-Dependent Toll-Like Receptor Expression and Responsiveness in Preadipocytes and Adipocytes
Batra, A., Pietsch, J., Fedke, I., Glauben, R., Okur, B., Stroh, T., Zeitz, M., & Siegmund, B. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060699 · Cited by 118
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
Petkar, K. C., Patil, S. M., Chavhan, S. S., Kaneko, K., Sawant, K. K., Kunda, N. K., & Saleem, I. Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040455 · Cited by 109
Presence and role of cytosine methylation in DNA viruses of animals
Hoelzer, K., Shackelton, L. A., & Parrish, C. R. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn121 · Cited by 104
Long-term presence of memory B-cells specific for different vaccine components
Buisman, A., de Rond, C. G. H., Öztürk, K., ten Hulscher, H. I., & van Binnendijk, R. S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.102 · Cited by 106
Antiinfective Applications of Toll-like Receptor 9 Agonists
KRIEG, A. M. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-021aw · Cited by 104
Self-citationKlinman, D. M. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.305 · Cited by 113
Self-citationThe immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
Weiner, G. J. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.4.455 · Cited by 104
Current Progress on aptamer-targeted Oligonucleotide Therapeutics
Dassie, J. P., & Giangrande, P. H. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.118 · Cited by 107
Sundling, C., Forsell, M. N. E., O'Dell, S. J., Feng, Y., Chakrabarti, B. K., Rao, S. S., Loré, K., Mascola, J. R., Wyatt, R. T., Douagi, I., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100025 · Cited by 103
Toll-like receptors and B cells: functions and mechanisms
Buchta, C. M., & Bishop, G. A. (2014) · Immunologic Research · doi:10.1007/s12026-014-8523-2 · Cited by 119
Self-citationvan den Beucken, J. J. J. P., Vos, M. R. J., Thüne, P. C., Hayakawa, T., Fukushima, T., Okahata, Y., Walboomers, X. F., Sommerdijk, N. A. J. M., Nolte, R. J. M., & Jansen, J. A. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.06.015 · Cited by 107
Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.
Brunner, C., Müller, B., & Wirth, T. C. (2005) · PubMed · doi:10.14670/hh-20.945 · Cited by 106
Cui, Z. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54011-2 · Cited by 126
Santulli-Marotto, S., Retter, M. W., Gee, R. J., Mamula, M. J., & Clarke, S. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80473-2 · Cited by 102
Jørgensen, J. B., Zou, J., Johansen, A., & Secombes, C. J. (2001) · Fish & Shellfish Immunology · doi:10.1006/fsim.2001.0344 · Cited by 103
Toll-like receptors and macrophage activation in atherosclerosis
Seneviratne, A. N., Sivagurunathan, B., & Monaco, C. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.08.021 · Cited by 120
Horner, A. A., Datta, S. K., Takabayashi, K., Belyakov, I. M., Hayashi, T., Cinman, N., Nguyen, M.-D., Uden, J. H. V., Berzofsky, J. A., Richman, D. D., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1584 · Cited by 104
Involvement of long noncoding RNAs in diseases affecting the central nervous system
Pastori, C., & Wahlestedt, C. (2012) · RNA Biology · doi:10.4161/rna.20482 · Cited by 100
Metal–Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis
Pang, Y., Fu, Y., Li, C., Wu, Z., Cao, W., Hu, X., Sun, X., He, W., Cao, X., Ling, D., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b02916 · Cited by 101
Transcriptional Regulation of the Human TLR9 Gene
Takeshita, F., Suzuki, K., Sasaki, S., Ishii, N., Klinman, D. M., & Ishii, K. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2552 · Cited by 101
Self-citationUse of CpG oligodeoxynucleotides as immunoprotective agents
Klinman, D. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.937 · Cited by 107
Self-citationExacerbation of Viral and Autoimmune Animal Models for Multiple Sclerosis by Bacterial DNA
Tsunoda, I., Tolley, N. D., Theil, D. J., Whitton, J. L., Kobayashi, H., & Fujinami, R. S. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00537.x · Cited by 101
Zhao, Q., Temsamani, J., ZHOU, R.-Z., & Agrawal, S. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.495 · Cited by 100
Abdul-Cader, M. S., Amarasinghe, A., & Abdul-Careem, M. F. (2016) · Archives of Virology · doi:10.1007/s00705-016-2904-x · Cited by 99
Fattal, E., & Barratt, G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00148.x · Cited by 98
RNA Recognition via TLR7 and TLR8
Hornung, V., Barchet, W., Schlee, M., & Hartmann, G. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-72167-3_4 · Cited by 116
Adjuvant formulations and delivery systems for DNA vaccines
Sasaki, S. (2003) · Methods · doi:10.1016/s1046-2023(03)00140-3 · Cited by 99
Cross-Linked Microparticles as Carriers for the Delivery of Plasmid DNA for Vaccine Development
Goh, S. L., Murthy, N., Xu, M., & Fréchet, J. M. J. (2004) · Bioconjugate Chemistry · doi:10.1021/bc034159n · Cited by 100
Ligands to Nucleic Acid–Specific Toll-Like Receptors and the Onset of Lupus Nephritis
Pawar, R. D., Patole, P. S., Ellwart, A., Lech, M., Segerer, S., Schlöndorff, D., & Anders, H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030263 · Cited by 100
Kawakami, S., Ito, Y., Charoensit, P., Yamashita, F., & Hashida, M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100669 · Cited by 99
Ferraccioli, G., Mecchia, F., Poi, E. D., & Fabris, M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.4.358 · Cited by 107
Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy.
Nishikawa, M., & Hashida, M. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.275 · Cited by 100
The revival of CpG oligonucleotide-based cancer immunotherapies
Adamus, T., & Kortylewski, M. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73887 · Cited by 97
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
Goyenvalle, A., Jimenez-Mallebrera, C., van Roon‐Mom, W., Sewing, S., Krieg, A. Μ., Arechavala‐Gomeza, V., & Andersson, P. U. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0061 · Cited by 109
Self-citationKandimalla, E. R., Bhagat, L., Li, Y., Yu, D., Wang, D., Cong, Y.-P., Song, S. S., Tang, J. X., Sullivan, T., & Agrawal, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501729102 · Cited by 98
Contribution of Plasmid DNA to Hepatotoxicity after Systemic Administration of Lipoplexes
Loisel, S., Le Gall, C., Doucet, L., Ferec, C., & Floch, V. (2001) · Human Gene Therapy · doi:10.1089/104303401300057405 · Cited by 98
Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells
Decker, T. W., Schneller, F., Kronschnabl, M., Dechow, T. N., Lipford, G. B., Wagner, H., & Peschel, C. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00144-2 · Cited by 100
Lu, B., Huang, Y. P., Huang, L., Bao, L., Zheng, Z., Chen, Z., Chen, J., Hu, Q., & Wang, H. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03231.x · Cited by 97
DNA Vaccines: Their Formulations, Engineering and Delivery
Kozak, M., & Hu, J. (2024) · Vaccines · doi:10.3390/vaccines12010071 · Cited by 115
TLR Agonists Promote Marginal Zone B Cell Activation and Facilitate T-Dependent IgM Responses
Rubtsov, A. V., Swanson, C. L., Troy, S., Strauch, P., Pelanda, R., & Torres, R. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3882 · Cited by 96
Jahrsdörfer, B., Wooldridge, J. E., Blackwell, S. E., Taylor, C. M., Griffith, T. S., Link, B. K., & Weiner, G. J. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0604373 · Cited by 96
CpG-induced immunomodulation and intracellular bacterial killing in a chicken macrophage cell line
Xie, H., Raybourne, R. B., Babu, U. S., Lillehoj, H. S., & Heckert, R. A. (2003) · Developmental & Comparative Immunology · doi:10.1016/s0145-305x(03)00079-x · Cited by 97
Carlow, D. A., Teh, S.-J., & Teh, H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.5.2348 · Cited by 98
Badros, A. Z., Goloubeva, O. G., Rapoport, A. P., Ratterree, B., Gahres, N., Meisenberg, B. R., Takebe, N., Heyman, M. R., Zwiebel, J. A., STREICHER, H. Z., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.381 · Cited by 101
Yao, X., Hu, J., Daniels, M., Shiran, H., Zhou, X., Yan, H., Lü, H., Zeng, Z., Wang, Q., Li, T., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15109 · Cited by 101
Challenges and strategies: The immune responses in gene therapy
Zhou, H., Liu, D., & Liang, C. (2004) · Medicinal Research Reviews · doi:10.1002/med.20009 · Cited by 98
G-Rich DNA Suppresses Systemic Lupus
Patole, P. S., Zecher, D., Pawar, R. D., Gro[Combining Diaeresis]ne, H.-J., Schlo[Combining Diaeresis]ndorff, D., & Anders, H.-J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005060658 · Cited by 97
Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs
KRIEG, A. M., Matson, S., & Fisher, E. F. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.133 · Cited by 96
Self-citationAntisense technology and prospects for therapy of viral infections and cancer
Wagner, R. W., & Flanagan, W. M. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(96)10053-8 · Cited by 96
The Essential Role of Evasion from Cell Death in Cancer
Kelly, G. L., & Strasser, A. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-385524-4.00002-7 · Cited by 112
CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes
József, L., Khreiss, T., & Filep, J. G. (2004) · The FASEB Journal · doi:10.1096/fj.04-2048fje · Cited by 104
Toll-like receptors and autoimmunity
Hurst, J., & von Landenberg, P. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.11.006 · Cited by 103
DNA containing CpG motifs induces angiogenesis
Zheng, M., Klinman, D. M., Gierynska, M., & Rouse, B. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132605599 · Cited by 95
Self-citationImpact of CpG methylation on structure, dynamics and solvation of cAMP DNA responsive element
Derreumaux, S. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.11.2314 · Cited by 95
Miura, K., Keister, D. B., Muratova, O. V., Sattabongkot, J., Long, C. A., & Saul, A. J. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-107 · Cited by 113
Klinman, D. M., Xie, H., Little, S. F., Currie, D., & Ivins, B. E. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.12.020 · Cited by 95
Self-citationEffects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors
Parks, R. J., Bramson, J. L., Wan, Y., Addison, C., & Graham, F. L. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8027-8034.1999 · Cited by 105
Pulmonary cytokine responses associated with PEI–DNA aerosol gene therapy
Gautam, A. K., Densmore, C. L., & Waldrep, J. C. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301369 · Cited by 95
The anti-DNA antibody: origin and impact, dogmas and controversies
Rekvig, O. P. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.69 · Cited by 98
Britigan, B. E., Lewis, T. S., Waldschmidt, M., McCormick, M. L., & Krieg, A. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2921 · Cited by 96
Self-citationHENRY, S. P., TAYLOR, J., MIDGLEY, L., LEVIN, A. A., & KORNBRUST, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.473 · Cited by 94
Tan, Y., Liu, F., Li, Z., Li, S., & Huang, L. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0311 · Cited by 94
Dias, N., Dheur, S., Nielsen, P. E., Gryaznov, S. M., Aerschot, A. A. V., Herdewijn, P. A., Hélène, C., & Saison-Behmoaras, T. E. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3277 · Cited by 96
Gene therapy for tissue repair and regeneration
Bonadio, J. F., Goldstein, S. A., & Levy, R. J. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00020-9 · Cited by 94
An Essential Role for Daxx in the Inhibition of B Lymphopoiesis by Type I Interferons
Góngora, R., Stephan, R. P., Zhang, Z., & Cooper, M. D. (2001) · Immunity · doi:10.1016/s1074-7613(01)00152-2 · Cited by 100
Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy
Barry, M. A., & Cooper, C. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1731 · Cited by 93
Innate Immune Stimulation Using 3D Wireframe DNA Origami
Du, R. R., Cedrone, E., Romanov, A. M., Falkovich, R., Dobrovolskaia, M. A., & Bathe, M. (2022) · ACS Nano · doi:10.1021/acsnano.2c06275 · Cited by 94
Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery
Bochot, A., Couvreur, P., & Fattal, E. (2000) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(99)00014-2 · Cited by 93
Vitamin A and Retinoic Acid in the Regulation of B-Cell Development and Antibody Production
Ross, A. C., Chen, Q., & Ma, Y. (2011) · Vitamins and hormones · doi:10.1016/b978-0-12-386960-9.00005-8 · Cited by 105
van Ojik, H. H., Bevaart, L., Dahle, C. E., Bakker, A., Jansen, M., van Vugt, M. J., van de Winkel, J. G. J., & Weiner, G. J. (2003) · PubMed · Cited by 99
CpG Oligodeoxynucleotides Enhance Host Defense during Murine Tuberculosis
Juffermans, N. P., Leemans, J. C., Florquin, S., Verbon, A., Kolk, A. H. J., Speelman, P., van Deventer, S. J. H., & van der Poll, T. (2002) · Infection and Immunity · doi:10.1128/iai.70.1.147-152.2002 · Cited by 93
Jakob, T., Walker, P., Krieg, A. Μ., von Stebut, E., Udey, M. C., & Vogel, J. C. (1999) · International Archives of Allergy and Immunology · doi:10.1159/000024163 · Cited by 102
Self-citationOptimization and delivery of plasmid DNA for vaccination
Jechlinger, W. (2006) · Expert Review of Vaccines · doi:10.1586/14760584.5.6.803 · Cited by 92
Yasuda, K., Ogawa, Y., Yamane, I., Nishikawa, M., & Takakura, Y. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0204089 · Cited by 93
Edelman, R. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.167 · Cited by 103
Lewis, P. J., & Babiuk, L. A. (1999) · Advances in virus research · doi:10.1016/s0065-3527(08)60367-x · Cited by 106
Nucleic acid immunization: concepts and techniques associated with third generation vaccines
Hasan, U. A., Abai, A. M., Harper, D. R., Wren, B. W., & Morrow, W. J. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00104-0 · Cited by 92
The role of superantigens in vasculitis
Tervaert, J. W. C., Popa, E. R., & Bos, N. A. (1999) · Current Opinion in Rheumatology · doi:10.1097/00002281-199901000-00005 · Cited by 92
Immunostimulatory DNA Prepriming: A Novel Approach for Prolonged Th1-Biased Immunity
Kobayashi, H., Horner, A. A., Takabayashi, K., Nguyen, M.-D., Huang, E., Cinman, N., & Raz, E. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1572 · Cited by 94
Modulation of Innate Cytokine Responses by Products of Helicobacter pylori
Meyer, F. P., Wilson, K. T., & James, S. P. (2000) · Infection and Immunity · doi:10.1128/iai.68.11.6265-6272.2000 · Cited by 92
Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-α in Two Murine Models of Colitis
Myers, K. J., Murthy, S., Flanigan, A., Witchell, D. R., Butler, M., Murray, S., Siwkowski, A. M., Goodfellow, D., Madsen, K. L., & Baker, B. F. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040329 · Cited by 93
McCluskie, M. J., & Davis, H. L. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00194-2 · Cited by 91
Leclerc, C., Dériaud, E., Rojas, M., & Whalen, R. G. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1161 · Cited by 91
Metadata
- Authors
- Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M.
- Affiliations
- University of Iowa (US)
- Center for Biologics Evaluation and Research (US)
- ORCID
- Venue
- Nature
- Published
- 1995-04
- Volume
- 374
- Issue
- 6522
- Pages
- 546-549
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2047366876
- Cited by
- 3,508
- References
- 28
- Citations by year
- 2026: 24 · 2025: 36 · 2024: 47 · 2023: 43 · 2022: 58 · 2021: 58 · 2020: 84 · 2019: 84 · 2018: 58 · 2017: 69 · 2016: 76 · 2015: 89 · 2014: 83 · 2013: 102 · 2012: 104
- FWCI
- 36.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CpG motifs, bacterial DNA, B cell activation, B cell proliferation, immunoglobulin secretion, antigen receptor signaling, CpG oligodeoxynucleotides, CpG suppression, antisense oligonucleotides, adjuvants
- MeSH terms
- Animals, B-Lymphocytes, Base Sequence, Cell Line, DNA, Bacterial, Escherichia coli, Lymphocyte Activation, Methylation, Mice, Inbred DBA, Molecular Sequence Data, Oligodeoxyribonucleotides, T-Lymphocytes, Dinucleoside Phosphates, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.